chan12.jpg
6-1.jpg
+
  • chan12.jpg
  • 6-1.jpg

Miglienel Calcium Capsule(24 tablets)

Exclusive national dosage form Fifteen provincial medical insurance Miglinide calcium capsules new generation of meal-time blood glucose regulator Glargine analogs are new structure of oral rapid-acting postprandial hypoglycemic drugs. Miglinide is the third new benzoic acid derivative hypoglycemic drug after Repaglinide and Naglinide, and is the latest generation of non-sulfonylurea insulin secretion promoter. It is the latest generation of non-sulfonylurea insulinotropic agent. It is known as "meal-time blood glucose regulator". Product Description [Approval Number] H20153263 [Approval Date] November 12, 2015 [Indications] Improve hyperglycemia in patients with type 2 diabetes mellitus [Usage and Dosage] Oral intake within 5 minutes before meals. Usually adults take 1 capsule each time, 3 times a day. Dosage can be adjusted according to the patient's therapeutic effect as appropriate. 【Specifications】10mg/capsule(based on Miglinide calcium)【Packaging】Aluminum plastic packaging, 10mg/capsule, 12 capsules/box; 24 capsules/box. Clinical features: 1, faster onset of action, shorter duration of action; 2, shorter duration of action, significantly reduce blood glucose and HbA1c levels; 3, high receptor selectivity, protection of pancreatic islet cells; 4, flexibility of administration, known as the "extracorporeal pancreas"; 5, first-line treatment for patients with early and mild diabetes mellitus; 6, high safety, good tolerance, long-term use. It can be used for a long time.

Category:

Miglienel Calcium Capsule


Miglienel Calcium Capsule
National Drug Code H20153263
Indications:
Improvement of postprandial hyperglycemia in patients with type 2 diabetes mellitus (limited to patients who do not have effective glycemic control with diet and exercise therapy or those who do not have effective glycemic control with the addition of alpha-glucosidase inhibitors to diet and exercise therapy).

Product Features:
1, 2017 new version of the national medical insurance;
2、 Faster onset of action, shorter duration of action;
3、 Stronger efficacy, significantly reduce blood glucose and HbA1c levels;
4, high receptor selectivity, protect pancreatic islet cells;
5. Flexible drug delivery, known as "extracorporeal pancreas";
6, The first-line therapeutic drug for early and mild diabetic patients;
7, high safety, good tolerance, can be used for a long time;
8, safe and effective in the treatment of diabetic nephropathy.
 

Product Message